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Background:  Chronic Anthracycline(A) cardiotoxicity represents a major limitation for its use in cancer patients (Pts). Data about the incidence 
and evolution of diastolic dysfunction following A treatment are scarce.
Methods:  80 consecutive pts receiving A-based chemotherapy (CHT)(75pts for breast cancer- 5pts for lymphomas) were included in this 
prospective study. All Pts underwent an echocardiogram and clinical evaluation at baseline, at the end of A CHT, 3 and 9 months after the end of 
A CHT. Pts receiving Trastuzumab(T) underwent an extra echocardiogram 6 and 12 months after the end of A CHT in order to monitor T toxicity. We 
recorded pulsed Tissue Doppler imaging at mitral annulus (septal and lateral), color M-mode propagation velocity(Vp) and standard mitral inflow 
diastolic parameters. Peak velocities in early diastole (E´), Vp of mitral inflow as well as mitral inflow parameters were measured.
Results:  At the end of follow-up (mean12.5±2 months) no pts developed clinical heart failure. Three pts(3.7%) had a mild decrease of ejection 
fraction (mean EF 50.3%). Twelve pts(15%) had baseline diastolic dysfunction. Of the remaining 68 patients 38 pts (56 %) developed diastolic 
dysfunction which was permanent in 29 pts (43%) and 29 pts (48%) didn’t develop significant diastolic changeChanges in diastolic parameters are 
showed in table 1.
Conclusions:  Diastolic dysfunction is commonly detected following anthracycline-based chemotherapy, although it is clinically silent one year 
after treatment. 
Serial Echocardiographic parameters at baseline and during follow-up( *denotes p value<0.05)
Baseline End of A CHT 3 months 6 months 9 months 12 months
E/A 1.21±0.3 1.05±0.3* 1.06±0.3* 1.05±0.2* 1.05±0.3* 1.08±0.2
DT(ms) 190.7±25 207.2±32* 204.5±33* 203.7±27* 205.8±34* 201.3±21
IVRT(ms) 88±7 93±12* 96±13* 92±13 94±12* 94±10
E´septum(cm/s) 9.8±2.3 8.6±2.3* 8.0±2.1* 8.7±2.6* 8.0±2.3* 8.0±2.7*
E´lateral (cm/s) 12.9±3.2 11.3±3.1* 10.9±3.3* 11.8±3.1 10.7±3.2* 10.9±3.3
Vp(cm/s) 56±9 49.7±10* 48.1±11* 44.0±8* 47.4±12* 47.6±12*
